Listen

Cast

Description

Julie Legg chats with Darrin Bull, spokesperson for ADHD New Zealand, about the changes newly announced by Pharmac that promise to reshape ADHD treatment accessibility in New Zealand. 

From December 1, 2024, Pharmac will fund lisdexamfetamine (Vyvanse), a next-generation ADHD medication, and remove the two-year psychiatrist renewal requirement for prescriptions. Darrin highlights the benefits of these changes, long-advocated by ADHD New Zealand, that aims to address significant barriers faced by those with ADHD.

KEY TAKEAWAYS

LINKS

Do you have a story to share? We'd love to hear from you if you have an inspiring ADHD experience/journey you'd like to share. We are looking for strategies that work for you, uplifting stories of overcoming adversity, or celebrating success.

Did you find this podcast helpful? Please subscribe if you'd like to hear more, or share with friends/family if you think there's a topic that may provide some insight. Our mission is to keep the ADHD conversation flowing and support each other.

Send us a text

Thanks for listening.